Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MNTA

Momenta Pharmaceuticals (MNTA) Stock Price, News & Analysis

Momenta Pharmaceuticals logo

About Momenta Pharmaceuticals Stock (NASDAQ:MNTA)

Key Stats

Today's Range
$52.48
$52.48
50-Day Range
$52.26
$52.49
52-Week Range
$12.21
$52.53
Volume
N/A
Average Volume
1.94 million shs
Market Capitalization
$6.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Momenta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MNTA Stock News Headlines

Johnson & Johnson Files for First FDA OK of Nipocalimab
Genoptix, Momenta Shares Headed for Gains
An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
Eastman Kodak, Rambus: After-Hours Trading
See More Headlines

MNTA Stock Analysis - Frequently Asked Questions

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its earnings results on Monday, August, 10th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biotechnology company had revenue of $6.61 million for the quarter, compared to the consensus estimate of $5.84 million. Momenta Pharmaceuticals had a negative net margin of 757.61% and a negative trailing twelve-month return on equity of 61.44%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Momenta Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Exelixis (EXEL), Gilead Sciences (GILD), Novavax (NVAX), Bristol Myers Squibb (BMY) and

Company Calendar

Last Earnings
8/10/2020
Today
10/09/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MNTA
CIK
1235010
Fax
N/A
Employees
131
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$290.05 million
Net Margins
-757.61%
Pretax Margin
N/A
Return on Equity
-61.44%
Return on Assets
-45.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.38
Quick Ratio
6.38

Sales & Book Value

Annual Sales
$23.87 million
Price / Sales
261.69
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.59 per share
Price / Book
11.43

Miscellaneous

Outstanding Shares
119,029,000
Free Float
N/A
Market Cap
$6.25 billion
Optionable
Optionable
Beta
1.71
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:MNTA) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners